Prab: CSV import

2024-12-03T11:27:04Z

CSV import

New page

{{Infobox drug
| name = Ilodecakin
| image = 
| width = 
| alt = 
| caption = 
| pronounce = 
| tradename = 
| synonyms = 
| drugs.com = 
| MedlinePlus = 
| pregnancy_AU = 
| pregnancy_US = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
| CAS_number = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 
| DrugBank = 
| ChemSpiderID = 
| UNII = 
| KEGG = 
| ChEBI = 
| ChEMBL = 
| synonyms = 
}}

'''Ilodecakin''' is a recombinant form of interleukin-10 (IL-10), a cytokine with anti-inflammatory properties. It is primarily investigated for its potential therapeutic effects in conditions characterized by excessive inflammation, such as [[rheumatoid arthritis]], [[Crohn's disease]], and [[sepsis]].

==Mechanism of Action==
Ilodecakin functions by mimicking the activity of endogenous interleukin-10, a cytokine that plays a crucial role in limiting immune responses to pathogens and preventing damage to the host. IL-10 achieves this by inhibiting the synthesis of pro-inflammatory cytokines, such as [[tumor necrosis factor-alpha]] (TNF-α), [[interleukin-1]] (IL-1), and [[interleukin-6]] (IL-6), thereby reducing inflammation and tissue damage.

==Clinical Applications==
Ilodecakin has been studied in various clinical trials for its efficacy in treating inflammatory diseases:

* '''Rheumatoid Arthritis''': Clinical trials have explored the use of ilodecakin in patients with rheumatoid arthritis, aiming to reduce joint inflammation and slow disease progression.
* '''Crohn's Disease''': As an inflammatory bowel disease, Crohn's disease involves chronic inflammation of the gastrointestinal tract. Ilodecakin has been investigated for its potential to induce remission and maintain long-term control of the disease.
* '''Sepsis''': In the context of sepsis, a life-threatening condition caused by the body's response to infection, ilodecakin has been evaluated for its ability to modulate the immune response and improve patient outcomes.

==Pharmacokinetics==
The pharmacokinetics of ilodecakin involve its absorption, distribution, metabolism, and excretion. As a protein-based therapeutic, it is typically administered via injection. The bioavailability, half-life, and clearance rates are subjects of ongoing research to optimize dosing regimens.

==Adverse Effects==
The administration of ilodecakin can lead to several adverse effects, which may include:

* Injection site reactions
* Flu-like symptoms
* Increased risk of infections due to immunosuppression

==Research and Development==
Ilodecakin is still under investigation, with ongoing studies aimed at better understanding its therapeutic potential and safety profile. Researchers are also exploring its use in combination with other therapies to enhance efficacy and reduce adverse effects.

==Also see==
* [[Interleukin-10]]
* [[Cytokine therapy]]
* [[Biologic therapy]]
* [[Autoimmune diseases]]

{{Reflist}}

[[Category:Immunology]]
[[Category:Biotechnology]]
[[Category:Anti-inflammatory agents]]

Ilodecakin - Revision history

Prab: CSV import